News
GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly ...
Built on the premise that only 30 per cent of workplace teams are considered high performing is tough to hear!
Business growth consultancy, 24HR Business Plan (24HRBP), has unveiled its newest offering: the 24 Hour High Performance ...
MANILA, Philippines — Watsons Philippines gathered the brilliant names in the health, wellness and beauty industry for its ...
Business Plan has introduced a data-driven coaching program to help leadership teams improve performance.The ...
During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...
11h
Stockhead on MSNDr Boreham’s Crucible: Sizing up the opportunity for ASX biotech AdheriumPlenty folk have an asthma puffer but few seem to know how to use it. Adherium says its Hailie device is improving compliance ...
Therapeutics Market is projected to be valued at USD 962.4 million in 2025, reaching USD 1,523.4 million by 2035, with a compound annual growth rate (CAGR) of 4.7% during the forecast period. The ...
The FTSE 100 was unmoved by simmering tensions in Israel and Iran, despite reports that the UK was scrambling to send fighter ...
GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...
21h
Pharmaceutical Technology on MSNNICE approves GSK’s belantamab mafodotin for blood cancerNHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results